Cited by 1,674Breast Cancer Treatment StudiesEstrogen and related hormone effectsEndometrial and Cervical Cancer Treatments

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Cuzick, Jack, Sestak, Ivana, Baum, Michael, Buzdar, Aman, Howell, Anthony, Dowsett, Mitch, Forbes, John F·2010·The Lancet Oncology

DOI 10.1016/s1470-2045(10)70257-6

Open this paper in CoChat — free account

Abstract

Background The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer. In this analysis, we assess the long-term outcomes after a median follow-up of 120 months.Methods We used a proportional hazards model to assess the primary endpoint of disease-free survival, and the secondary endpoints of time to recurrence, time to distant recurrence, incidence of new contralateral breast cancer, overall survival, and death with or without recurrence in all randomised patients (anastrozole n=3125, tamoxifen n=3116) and hormone-receptor-positive patients (anastrozole n=2618, tamoxifen n=2598). After treatment completion, we continued to collect data on fractures and serious adverse events in a masked fashion (safety population: anastrozole n=3092, tamoxifen n=3094). This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN18233230.Findings Patients were followed up for a median of 120 months (range 0-145); there were 24,522 woman-years of follow-up in the anastrozole group and 23,950 woman-years in the tamoxifen group. In the full study population, there were significant improvements in the anastrozole group compared with the tamoxifen group for disease-free survival (hazard ratio [HR] 0·91, 95% CI 0·83-0·99; p=0·04), time to recurrence (0·84, 0·75-0·93; p=0·001), and time to distant recurrence (0·87, 0·77-0·99; p=0·03). For hormone-receptor-positive patients, the results were also significantly in favour of the anastrozole group for disease-free survival (HR 0·86, 95% CI 0·78-0·95; p=0·003), time to recurrence (0·79, 0·70-0·89; p=0·0002), and time to distant recurrence (0·85, 0·73-0·98; p=0·02). In hormone-receptor-positive patients, absolute differences in time to recurrence between anastrozole and tamoxifen increased over time (2·7% at 5 years and 4·3% at 10 years) and recurrence rates remained significantly lower on anastrozole than tamoxifen after treatment completion (HR 0·81, 95% CI 0·67-0·98; p=0·03), although the carryover benefit was smaller after 8 years. There was weak evidence of fewer deaths after recurrence with anastrozole compared with tamoxifen treatment in the hormone-receptor-positive subgroup (HR 0·87, 95% CI 0·74-1·02; p=0·09), but there was little difference in overall mortality (0·95, 95% CI 0·84-1·06; p=0·4). Fractures were more frequent during active treatment in patients receiving anastrozole than those receiving tamoxifen (451 vs 351; OR 1·33, 95% CI 1·15-1·55; p<0·0001), but were similar in the post-treatment follow-up period (110 vs 112; OR 0·98, 95% CI 0·74-1·30; p=0·9). Treatment-related serious adverse events were less common in the anastrozole group than the tamoxifen group (223 anastrozole vs 369 tamoxifen; OR 0·57, 95% CI 0·48-0·69; p<0·0001), but were similar after treatment completion (66 vs 78; OR 0·84, 95% CI 0·60-1·19; p=0·3). No differences in non-breast cancer causes of death were apparent and the incidence of other cancers was similar between groups (425 vs 431) and continue to be higher with anastrozole for colorectal (66 vs 44) and lung cancer (51 vs 34), and lower for endometrial cancer (six vs 24), melanoma (eight vs 19), and ovarian cancer (17 vs 28). No new safety concerns were reported.Interpretation These data confirm the long-term superior efficacy and safety of anastrozole over tamoxifen as initial adjuvant therapy for postmenopausal women with hormone-sensitive early breast cancer.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(10)70257-6

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(2005) · The Lancet · doi:10.1016/s0140-6736(05)66544-0 · Cited by 7,626
Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Self-citation
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
Self-citation
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
Nabholtz, J., Buzdar, A. U., Pollak, M., Harwin, W. N., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 989
Self-citation
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Williams, N. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 918
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Coombes, R. C., Kilburn, L., Snowdon, C. F., Paridaens, R., Coleman, R., Jones, S., Jassem, J., van de Velde, C., Delozier, T., Álvarez, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60200-1 · Cited by 901
Self-citation

Show all 27 references

Sorted by citations

Items 301–400 of 1,000

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
Rosso, R., D’Alonzo, M., Bounous, V. E., Actis, S., Cipullo, I., Salerno, E., & Biglia, N. (2023) · Current Oncology · doi:10.3390/curroncol30020112 · Cited by 62
Clinical utilities of aromatase inhibitors in breast cancer
Chumsri, S. (2015) · International Journal of Women s Health · doi:10.2147/ijwh.s69907 · Cited by 57
Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)
Kubo, M., Kanaya, N., Petrossian, K., Ye, J., Warden, C., Liu, Z., Nishimura, R., Osako, T., Okido, M., Shimada, K., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2332-x · Cited by 58
Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer
Güth, U., Huang, D. J., Schötzau, A., Zanetti‐Dällenbach, R., Holzgreve, W., Bitzer, J., & Wight, E. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604525 · Cited by 58
Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection
Zhou, H., Huang, H., Shi, J., Zhao, Y., Dong, Q., Jia, H., Liu, Y., Ye, Q., Sun, H., Zhu, X., et al. (2010) · Gut · doi:10.1136/gut.2010.218404 · Cited by 56
Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments
Shapiro, C. L. (2020) · Cancers · doi:10.3390/cancers12113094 · Cited by 59
Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy
Diana, A., Carlino, F., Giunta, E. F., Franzese, E., Guerrera, L. P., Lauro, V. D., Ciardiello, F., Daniele, B., & Orditura, M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00835-2 · Cited by 57
Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series
Zagouri, F., Sergentanis, T. Ν., Koutoulidis, V., Sparber, C., Steger, G. G., Dubsky, P. C., Zografos, G. C., Ψαλτοπούλου, Θ., Gnant, M., Dimopoulos, M. A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.255 · Cited by 55
Increasing trend of contralateral prophylactic mastectomy: What are the factors behind this phenomenon?
Soran, A., Polat, A. K., Johnson, R. R., & McGuire, K. P. (2014) · The Surgeon · doi:10.1016/j.surge.2014.02.005 · Cited by 55
Effects of Exemestane and Tamoxifen Treatment on Bone Texture Analysis Assessed by TBS in Comparison With Bone Mineral Density Assessed by DXA in Women With Breast Cancer
Kalder, M., Hans, D. B., Kyvernitakis, I., Lamy, O., Bauer, M., & Hadji, P. (2013) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2013.03.003 · Cited by 55
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04)
Takei, H., Ohsumi, S., Shimozuma, K., Takehara, M., Suemasu, K., Ohashi, Y., & Hozumi, Y. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1943-y · Cited by 55
Phase II Parallel Group Study Showing Comparable Efficacy Between Premenopausal Metastatic Breast Cancer Patients Treated With Letrozole Plus Goserelin and Postmenopausal Patients Treated With Letrozole Alone As First-Line Hormone Therapy
Park, I. H., Ro, J., Lee, K. S., Kim, E.-A. L., Kwon, Y., Nam, B.-H., Jung, S., Lee, S., Kim, S. W., & Kang, H. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5884 · Cited by 55
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial
Derks, M. G. M., Blok, E. J., Seynaeve, C., Nortier, J. W. R., Kranenbarg, E. M., Liefers, G., Putter, H., Kroep, J. R., Rea, D. W., Hasenburg, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30419-9 · Cited by 59
Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer
van Hellemond, I. E. G., Geurts, S. M. E., & Tjan‐Heijnen, V. C. G. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0541-1 · Cited by 57
Interpreting Plasma Estrogen Levels in Breast Cancer: Caution Needed
Folkerd, E. J., Lønning, P. E., & Dowsett, M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.9411 · Cited by 53
Self-citation
Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies
Özyurt, R., & Özpolat, B. (2022) · Cancers · doi:10.3390/cancers14215206 · Cited by 55
Does regional anaesthesia and analgesia or opioid analgesia influence recurrence after primary cancer surgery? An update of available evidence
Ash, S. A., & Buggy, D. J. (2013) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2013.10.005 · Cited by 55
Pharmacogenetics of Endocrine Therapy for Breast Cancer
Higgins, M. J., & Stearns, V. (2010) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182545 · Cited by 54
Surgical options for male breast cancer
Fentiman, I. S. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4952-2 · Cited by 57
The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of ARomatase inhibitors AssessmenT in daily practice through educational approach (CARIATIDE) study
Neven, P., Markopoulos, C., Tanner, M., Marty, M., Kreienberg, R., Atkins, L., Franquet, A., Gnant, M., Neciosup, S., Tesarova, P., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.02.009 · Cited by 53
Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes
Seruga, B., & Tannock, I. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5594 · Cited by 53
Aromatase Inhibitor-Associated Bone Fractures: A Case-Cohort GWAS and Functional Genomics
Liu, M., Goss, P. E., Ingle, J. N., Kubo, M., Furukawa, Y., Batzler, A. J., Jenkins, G. D., Carlson, E. E., Nakamura, Y., Schaid, D. J., et al. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1147 · Cited by 53
Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer
Fox, E. M., Arteaga, C. L., & Miller, T. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00145 · Cited by 54
Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy
Datta, M., & Schwartz, G. G. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.07.002 · Cited by 53
Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus
Hadji, P., Coleman, R. E., & Gnant, M. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.015 · Cited by 52
Current Knowledge on Contralateral Prophylactic Mastectomy Among Women with Sporadic Breast Cancer
Brewster, A. M., & Parker, P. A. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0022 · Cited by 52
Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens
Stabile, L. P., Rothstein, M. E., Cunningham, D. E., Land, S. R., Đačić, S., Keohavong, P., & Siegfried, J. M. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs260 · Cited by 54
Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation
Johnston, S. J., & Cheung, K. (2018) · Oncology and Therapy · doi:10.1007/s40487-018-0062-x · Cited by 52
Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer
Parker, P. A., Peterson, S. K., Shen, Y., Bedrosian, I., Black, D. M., Thompson, A. M., Nelson, J. C., DeSnyder, S. M., Cook, R. L., Hunt, K. K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.6442 · Cited by 52
Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study
Laroche, F., Perrot, S., Medkour, T., Cottu, P. H., Pierga, J., Lotz, J., Beerblock, K., Tournigand, C., Chauvenet, L., Bouhassira, D., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187165 · Cited by 52
The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status
Schonfeld, S. J., Curtis, R. E., Anderson, W. F., & de González, A. B. (2012) · Cancer Causes & Control · doi:10.1007/s10552-012-0054-3 · Cited by 51
Predictors of response to exemestane as primary endocrine therapy in estrogen receptor–positive breast cancer
Yamashita, H., Takahashi, S., Ito, Y., Yamashita, T., Ando, Y., Toyama, T., Sugiura, H., Yoshimoto, N., Kobayashi, S., Fujii, Y., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01274.x · Cited by 52
A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women
Cardoso, F., Bischoff, J., Brain, E. G. C., Zotano, Á. G., Lück, H., Tjan‐Heijnen, V. C. G., Tanner, M., & Aapro, M. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.06.011 · Cited by 52
A model for individualized risk prediction of contralateral breast cancer
Chowdhury, M., Euhus, D., Onega, T., Biswas, S., & Choudhary, P. K. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4039-x · Cited by 51
Recent Improvement in the Long-term Survival of Breast Cancer Patients by Age and Stage in Japan
Yoshimura, A., Ito, H. M., Nishino, Y., Hattori, M., Matsuda, T., Miyashiro, I., Nakayama, T., Iwata, H., Matsuo, K., Tanaka, H., et al. (2018) · Journal of Epidemiology · doi:10.2188/jea.je20170103 · Cited by 51
Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy
Muhsen, S., Moo, T.-A. S., Patil, S. N., Stempel, M. M., Powell, S. N., Morrow, M., & El-Tamer, M. B. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6422-9 · Cited by 50
Cancer Treatment-Induced Bone Loss in women with breast cancer
Hadji, P. (2015) · BoneKEy Reports · doi:10.1038/bonekey.2015.60 · Cited by 50
Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?
Lønning, P. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.019 · Cited by 50
Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients
Ligibel, J. A., O’Malley, A. J., Fisher, M. D., Daniel, G. W., Winer, E. P., & Keating, N. L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1754-1 · Cited by 50
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study
Aihara, T., Takatsuka, Y., Ohsumi, S., Aogi, K., Hozumi, Y., Imoto, S., Mukai, H., Iwata, H., Watanabe, T., Shimizu, C., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0888-x · Cited by 51
Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors
Akli, S., Bui, T. N., Wingate, H. F., Biernacka, A., Moulder, S., Tucker, S. L., Hunt, K. K., & Keyomarsi, K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1787 · Cited by 50
Molecular Testing in Breast Cancer: A Guide to Current Practices
Hagemann, I. S. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0051-ra · Cited by 50
Older cancer patients in cancer clinical trials are underrepresented. Systematic literature review of almost 5000 meta- and pooled analyses of phase III randomized trials of survival from breast, prostate and lung cancer
Dunn, C., Wilson, A. J., & Sitas, F. (2017) · Cancer Epidemiology · doi:10.1016/j.canep.2017.11.002 · Cited by 50
CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients
Jernström, H., Bågeman, E., Rose, C., Jönsson, P.-E., & Ingvar, C. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605428 · Cited by 50
Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?
Güth, U., Myrick, M. E., Schötzau, A., Kilic, N., & Schmid, S. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1668-y · Cited by 51
Obesity and female malignancies
Benedetto, C., Salvagno, F., Canuto, E. M., & Gennarelli, G. (2015) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2015.01.003 · Cited by 49
Caring for Survivors of Breast Cancer: Perspective of the Primary Care Physician
Smith, S. L., Wai, E. S., Alexander, C., & Singh‐Carlson, S. (2011) · Current Oncology · doi:10.3747/co.v18i5.793 · Cited by 49
Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
Carvajal‐Hausdorf, D., Mani, N. L., Velcheti, V., Schalper, K. A., & Rimm, D. L. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0285-7 · Cited by 51
Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
Liu, X., Ma, D., Xu, X., Jin, X., Yu, K., Jiang, Y., & Shao, Z.-M. (2018) · Theranostics · doi:10.7150/thno.29164 · Cited by 49
Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer
Edwards, B. J.-A., Raisch, D. W., Shankaran, V., McKoy, J. M., Gradishar, W. J., Bunta, A. D., Samaras, A. T., Boyle, S. N., Bennett, C. L., West, D. P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1595 · Cited by 51
The effect of exemestane or tamoxifen on markers of bone turnover: Results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial
Hadji, P., Ziller, M., Kieback, D., Menschik, T., Kalder, M., Kuck, J., & Hasenburg, A. (2009) · The Breast · doi:10.1016/j.breast.2009.03.003 · Cited by 48
Anastrozole
Sanford, M., & Plosker, G. L. (2008) · Drugs · doi:10.2165/00003495-200868090-00007 · Cited by 49
Compliance and persistence of endocrine adjuvant breast cancer therapy
Güth, U., Myrick, M. E., Kilic, N., Eppenberger‐Castori, S., & Schmid, S. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1801-y · Cited by 49
Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer
Chen, X., Zhao, M., Hao, M., Sun, X., Wang, J., Mao, Y., Zu, L., Liu, J., Shen, Y., Wang, J., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0212 · Cited by 50
Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?
Kemp, A., Preen, D. B., Saunders, C. M., Boyle, F. M., Bulsara, M. K., Malacova, E., & Roughead, E. E. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-282 · Cited by 47
Multicriteria decision analysis in oncology
Adunlin, G., Diaby, V., Montero, A. J., & Xiao, H. (2014) · Health Expectations · doi:10.1111/hex.12178 · Cited by 48
Interventions for the Treatment of Aromatase Inhibitor–Associated Arthralgia in Breast Cancer Survivors
Yang, G. S., Kim, H. J., Griffith, K. A., Zhu, S., Dorsey, S. G., & Renn, C. L. (2016) · Cancer Nursing · doi:10.1097/ncc.0000000000000409 · Cited by 48
Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer
Zhang, X., Wang, Y., Li, X., Wu, J., Zhao, L., Li, W., & Liu, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00280 · Cited by 48
Aquatic exercise in a chest-high pool for hormone therapy-induced arthralgia in breast cancer survivors: a pragmatic controlled trial
Cantarero‐Villanueva, I., Fernández‐Lao, C., Caro-Morán, E., Morillas-Ruiz, J. M., Galiano‐Castillo, N., Díaz‐Rodríguez, L., & Arroyo‐Morales, M. (2012) · Clinical Rehabilitation · doi:10.1177/0269215512448256 · Cited by 48
Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors
Matthews, A., Hinton, S. P., Stanway, S. J., Lyon, A. R., Smeeth, L. L., Lund, J. L., & Bhaskaran, K. (2020) · Heart · doi:10.1136/heartjnl-2020-317510 · Cited by 47
The Alberta moving beyond breast cancer (AMBER) cohort study: a prospective study of physical activity and health-related fitness in breast cancer survivors
Courneya, K. S., Vallance, J. K., Culos-Reed, S. N., McNeely, M. L., Bell, G. J., Mackey, J. R., Yasui, Y., Yan Yuan, A., Matthews, C. E., Lau, D. C. W., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-525 · Cited by 49
Contralateral risk-reducing mastectomy in sporadic breast cancer
Murphy, J. A., Milner, T. D., & OʼDonoghue, J. M. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70047-0 · Cited by 47
IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer
Zhang, Y.-H., Wester, L., He, J., Geiger, T., Moerkens, M., Siddappa, R., Helmijr, J., Timmermans, M. M., Look, M. P., van Deurzen, C. H. M., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0027-9 · Cited by 48
A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach.
Gul, A., Leyland-Jones, B., Dey, N., & De, P. K. (2018) · Europe PMC (PubMed Central) · Cited by 45
Inhibition of Dimethylarginine Dimethylaminohydrolase (DDAH) Enzymes as an Emerging Therapeutic Strategy to Target Angiogenesis and Vasculogenic Mimicry in Cancer
Hulin, J.-A., Александровна, Г. Е., Jarzebska, N., Rodionov, R. N., Mangoni, A. A., & Tommasi, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01455 · Cited by 46
No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA)
Cai, B., Simon, J. A., Villa, P., Biglia, N., Panay, N., Djumaeva, S., Particco, M., Kanakamedala, H., & Altomare, C. J. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.06.021 · Cited by 47
Cancer Treatment-Related Bone Disease
Brown, S. A., & Guise, T. A. (2009) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v19.i1.20 · Cited by 47
Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis
Artigalás, O., Vanni, T., Hutz, M. H., Ashton‐Prolla, P., & Schwartz, I. V. D. (2015) · BMC Medicine · doi:10.1186/s12916-015-0373-9 · Cited by 46
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer
Dalmau, E., Armengol-Alonso, A., Muñoz-Mateu, M., & Seguí, M. Á. (2014) · The Breast · doi:10.1016/j.breast.2014.09.006 · Cited by 50
Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options
Lombard, J. M., Zdenkowski, N., Wells, K., Beckmore, C., Reaby, L., Forbes, J., & Chirgwin, J. H. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-3001-5 · Cited by 45
Self-citation
Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer
Lenihan, D. J., & Esteva, F. J. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0112 · Cited by 47
Design and Synthesis of Norendoxifen Analogues with Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities
Lv, W., Liu, J., Skaar, T. C., Flockhart, D. A., & Cushman, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501218e · Cited by 46
A prospective study of aromatase inhibitor‐associated musculoskeletal symptoms and abnormalities on serial high‐resolution wrist ultrasonography
Henry, N. L., Jacobson, J. A., Banerjee, M., Hayden, J., Smerage, J. B., Poznak, C. H. V., Storniolo, A. M., Stearns, V., & Hayes, D. F. (2010) · Cancer · doi:10.1002/cncr.25385 · Cited by 46
Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients
Jaque, J. M., Macdonald, H., Brueggmann, D., Patel, S. K., Azen, C. G., Clarke, N. J., & Stanczyk, F. Z. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-5 · Cited by 46
Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post‐menopausal women with early breast cancer
Brauch, H. B., & Schwab, M. G. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12229 · Cited by 45
Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy
Kalder, M., Kyvernitakis, I., Albert, U. ‐., Baier-Ebert, M., & Hadji, P. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2955-3 · Cited by 45
Thrombophilic state in cancer, Part I: Biology, incidence, and risk factors
DiPasco, P. J., Misra, S., Koniaris, L. G., & Moffat, F. L. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21925 · Cited by 45
PRKDC regulates chemosensitivity and is a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients
Sun, G., Yang, L., Dong, C., Ma, B., Shan, M., & Ma, B. (2017) · Oncology Reports · doi:10.3892/or.2017.5634 · Cited by 45
Epigenetic arginine methylation in breast cancer: emerging therapeutic strategies
Wang, S.-C., Dowhan, D. H., & Muscat, G. E. O. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0224 · Cited by 44
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study
Henry, N. L., Pchejetski, D., A’Hern, R., Nguyen, A., Charles, P. J., Waxman, J., Li, L., Storniolo, A. M., Hayes, D. F., Flockhart, D. A., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605768 · Cited by 45
HER 2 overexpression a major risk factor for recurrence in pT1a‐bN0M0 breast cancer: results from a F rench regional cohort
Rouanet, P., Roger, P., Rousseau, E., Thibault, S., Romieu, G., Mathieu, A., Cretin, J., Barneon, G., Granier, M., Maran-Gonzalez, A., et al. (2014) · Cancer Medicine · doi:10.1002/cam4.167 · Cited by 45
Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer
Dowsett, M., Šestak, I., Buus, R., López‐Knowles, E., Mallon, E., Howell, A., Forbes, J., Buzdar, A. U., & Cuzick, J. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2842 · Cited by 44
Self-citation
Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study
Yeo, B. J., Zabaglo, L. A., Hills, M., Dodson, A. R., Smith, I., & Dowsett, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.222 · Cited by 44
Self-citation
Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials
Zhou, W., Ding, Q., Chen, L., Liu, X., & Wang, S. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1556-5 · Cited by 44
Fracture incidence after 3 years of aromatase inhibitor therapy
Bouvard, B., Soulié, P., Hoppé, E., Georgin-Mège, M., Royer, M., Mesgouez‐Nebout, N., Lassalle, C., Cellier, P., Jadaud, E., Abadie‐Lacourtoisie, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu008 · Cited by 45
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ
Chen, Y., DeVries, S., Anderson, J., Lessing, J. N., Swain, R., Chin, K., Shim, V., Esserman, L. J., Waldman, F. M., & Hwang, E. S. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-285 · Cited by 44
The Role of Sex in the Pathophysiology of Pulmonary Hypertension
Docherty, C. K., Harvey, K. Y., Mair, K. M., Griffin, S., Denver, N., & MacLean, M. R. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77932-4_31 · Cited by 44
Adherence evaluation of endocrine treatment in breast cancer: methodological aspects
Oberguggenberger, A., Sztankay, M. J., Beer, B., Schubert, B., Meraner, V., Oberacher, H., Kemmler, G., Giesinger, J. M., Gamper, E., Sperner‐Unterweger, B., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-474 · Cited by 45
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer
Chlebowski, R. T., Cuzick, J. M., Amakye, D. D., Bauerfeind, I., Buzdar, A. U., Chia, S., Cutuli, B., Linforth, R., Maass, N., Noguchi, S., et al. (2009) · The Breast · doi:10.1016/s0960-9776(09)70002-5 · Cited by 43
Self-citation
Management of primary and advanced breast cancer in older unfit patients (medical treatment)
Aapro, M., Monfardini, S., Jirillo, A., & Basso, U. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.04.002 · Cited by 43
Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data
Lintermans, A., Laenen, A., CALSTER, B. V., Hoydonck, M. V., Pans, S., Verhaeghe, J., Westhovens, R., Henry, N. L., Wildiers, H. P. M. W., Paridaens, R., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds290 · Cited by 44
The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
Engels, C. C., Charehbili, A., van de Velde, C. J. �., Bastiaannet, E., Sajet, A., Putter, H., van Vliet, E. A., van Vlierberghe, R. L. P., Smit, V. T. H. B. M., Bartlett, J. M. S., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3269-7 · Cited by 44
Cáncer de mama
Angulo, M. M., Yustos, M. A., León, M. L. V., & Soto, M. Á. D. M. (2013) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(13)70517-1 · Cited by 44
Contralateral Prophylactic Mastectomy: Challenging Considerations for the Surgeon
Angelos, P., Bedrosian, I., Euhus, D., Herrmann, V. M., Katz, S. J., & Pusic, A. L. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4758-y · Cited by 42
Indications of Clinical and Genetic Predictors for Aromatase Inhibitors Related Musculoskeletal Adverse Events in Chinese Han Women with Breast Cancer
Wang, J., Lu, K., Song, Y., Xie, L., Zhao, S., Wang, Y., Sun, W., Liu, L., Zhao, H., Tang, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068798 · Cited by 41
The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer
Schwartz, J., Shajahan‐Haq, A. N., & Clarke, R. C. (2011) · International Journal of Breast Cancer · doi:10.4061/2011/912102 · Cited by 42
Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial
Mote, P. A., Gompel, A., Howe, C., Hilton, H. N., Šestak, I., Cuzick, J. M., Dowsett, M., Hugol, D., Forgez, P., Byth, K., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3397-0 · Cited by 42
Self-citation
The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies
Hadji, P., Asmar, L., van Nes, J. G. H., Menschik, T., Hasenburg, A., Kuck, J., Nortier, J. W. R., van de Velde, C. J. �., Jones, S. E., & Ziller, M. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0964-y · Cited by 42
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors
Lazarus, P. J., & Sun, D. (2009) · Drug Metabolism Reviews · doi:10.3109/03602530903208652 · Cited by 42
The Manchester guidelines for contralateral risk-reducing mastectomy
Basu, N. N., Ross, G. L., Evans, D. G., & Barr, L. C. (2015) · World Journal of Surgical Oncology · doi:10.1186/s12957-015-0638-y · Cited by 42

Authors: Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F.
Affiliations: University of London (GB)
Cancer Research UK (GB)
The University of Texas MD Anderson Cancer Center (US)
Royal Marsden Hospital (GB)
University of Newcastle Australia (AU)
Corresponding author: Cuzick, Jack
ORCID: Cuzick, Jack
Baum, Michael
Buzdar, Aman
Howell, Anthony
Dowsett, Mitch
Forbes, John F
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2010-12
Volume: 11
Issue: 12
Pages: 1135-1141
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(10)70257-6
OpenAlex: W2112780046
Cited by: 1,674
References: 27
Citations by year: 2026: 21 · 2025: 35 · 2024: 50 · 2023: 54 · 2022: 63 · 2021: 64 · 2020: 85 · 2019: 66 · 2018: 85 · 2017: 98 · 2016: 101 · 2015: 116 · 2014: 125 · 2013: 148 · 2012: 121
FWCI: 51.63
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Research Explorer (The University of Manchester) (submittedVersion)
NOVA (University of Newcastle Australia) (submittedVersion)
Funders: AstraZeneca
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords: anastrozole, tamoxifen, adjuvant endocrine therapy, early breast cancer, postmenopausal women, disease-free survival, time to recurrence, distant recurrence, hormone receptor-positive breast cancer, contralateral breast cancer, overall survival, fracture risk, long-term outcomes, ATAC trial, aromatase inhibitors, selective estrogen receptor modulators, breast cancer recurrence
MeSH terms: Anastrozole, Administration, Oral, Breast Neoplasms, Female, Follow-Up Studies, Humans, Neoplasm Staging, Nitriles, Tamoxifen, Triazoles, Treatment Outcome, Chemotherapy, Adjuvant, Postmenopause, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks